Under construction – not a live service
Sign in
Taking peopleNo phase

Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Saudi Arabia2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
77 people, planned
Started
10 Mar 2025
Planned end
30 Sept 2026
Type of study
Observational
Treatments tested
  • Secukinmab
Record updated
30 December 2025

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Male or Female adult patients ≥18 years of age at the time of data collection
  • Patient with a confirmed diagnosis of active moderate to severe HS
  • Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label
  • Patients can be using antibiotics or have undergone surgery as per routine clinical practice
  • Patients agree to sign an informed consent form (ICF) to be able to complete the questionnaires

Who cannot take part

  • A history of off-label indication uses of biological treatment or JAK inhibitor
  • Patients not fulfilling any of the above-mentioned inclusion criteria
  • Patient's refusal to be included in the study or refusal to sign the ICF

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment satisfaction as measured by the treatment satisfaction questionnaire for medication (TSQM) at week 24 among moderate to severe HS patients.

The group in the trial

  • Secukinumab

    Patients who are newly initiated on Secukinumab

    Treatment: Secukinmab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Survey Assessing Prospective Patient's Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Cosentyx (Secukinumab) in Routine Clinical Practice in Saudi Arabia: ILLUMINATE-SA
Fit questions
Built from NCT06785779, who can take part
Record updated
30 December 2025